Danielle E McCarthy1, Lemma Ebssa2, Katie Witkiewitz3, Saul Shiffman4. 1. Department of Psychology, Rutgers, The State University of New Jersey. 2. Institute for Health, Health Care Policy, and Aging Research, Rutgers, The State University of New Jersey. 3. Department of Psychology, University of New Mexico. 4. Department of Psychology, University of Pittsburgh.
Abstract
OBJECTIVE: Knowledge of smoking change processes may be enhanced by identifying pathways to stable abstinence. We sought to identify latent classes of smokers based on their day-to-day smoking status in the first weeks of a cessation attempt. We examined treatment effects on class membership and compared classes on baseline individual differences and 6-month abstinence rates. METHOD: In this secondary analysis of a double-blind randomized placebo-controlled clinical trial (N = 1,433) of 5 smoking cessation pharmacotherapies (nicotine patch, nicotine lozenge, bupropion SR, patch and lozenge, or bupropion SR and lozenge), we conducted repeated-measures latent class analysis of daily smoking status (any smoking vs. none) for the first 27 days of a quit attempt. Treatment and covariate relations with latent class membership were examined. Distal outcome analysis compared confirmed 6-month abstinence rates among the latent classes. RESULTS: A 5-class solution was selected. Three-quarters of smokers were in stable smoking or abstinent classes, but 25% were in classes with unstable abstinence probabilities over time. Active treatment (compared to placebo), and particularly the patch and lozenge combination, promoted early quitting. Latent classes differed in 6-month abstinence rates and on several baseline variables, including nicotine dependence, quitting history, self-efficacy, sleep disturbance, and minority status. CONCLUSIONS: Repeated-measures latent class analysis identified latent classes of smoking change patterns affected by treatment, related to known risk factors, and predictive of distal outcomes. Tracking behavior early in a change attempt may identify prognostic patterns of change and facilitate adaptive treatment planning. (c) 2015 APA, all rights reserved).
RCT Entities:
OBJECTIVE: Knowledge of smoking change processes may be enhanced by identifying pathways to stable abstinence. We sought to identify latent classes of smokers based on their day-to-day smoking status in the first weeks of a cessation attempt. We examined treatment effects on class membership and compared classes on baseline individual differences and 6-month abstinence rates. METHOD: In this secondary analysis of a double-blind randomized placebo-controlled clinical trial (N = 1,433) of 5 smoking cessation pharmacotherapies (nicotine patch, nicotinelozenge, bupropion SR, patch and lozenge, or bupropion SR and lozenge), we conducted repeated-measures latent class analysis of daily smoking status (any smoking vs. none) for the first 27 days of a quit attempt. Treatment and covariate relations with latent class membership were examined. Distal outcome analysis compared confirmed 6-month abstinence rates among the latent classes. RESULTS: A 5-class solution was selected. Three-quarters of smokers were in stable smoking or abstinent classes, but 25% were in classes with unstable abstinence probabilities over time. Active treatment (compared to placebo), and particularly the patch and lozenge combination, promoted early quitting. Latent classes differed in 6-month abstinence rates and on several baseline variables, including nicotine dependence, quitting history, self-efficacy, sleep disturbance, and minority status. CONCLUSIONS: Repeated-measures latent class analysis identified latent classes of smoking change patterns affected by treatment, related to known risk factors, and predictive of distal outcomes. Tracking behavior early in a change attempt may identify prognostic patterns of change and facilitate adaptive treatment planning. (c) 2015 APA, all rights reserved).
Authors: Megan E Piper; Thomas M Piasecki; E Belle Federman; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Timothy B Baker Journal: J Consult Clin Psychol Date: 2004-04
Authors: Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark Journal: J Consult Clin Psychol Date: 2006-04
Authors: Domenic A Ciraulo; Qunming Dong; Bernard L Silverman; David R Gastfriend; Helen M Pettinati Journal: J Clin Psychiatry Date: 2008-02 Impact factor: 4.384
Authors: Danielle E McCarthy; Thomas M Piasecki; Daniel L Lawrence; Douglas E Jorenby; Saul Shiffman; Timothy B Baker Journal: Addiction Date: 2008-09 Impact factor: 6.526
Authors: Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Caryn Lerman; Neal Benowitz; Michael C Fiore; Timothy B Baker Journal: Nicotine Tob Res Date: 2008-06 Impact factor: 4.244
Authors: Lorra Garey; Kara Manning; Danielle E McCarthy; Matthew W Gallagher; Justin M Shepherd; Michael F Orr; Norman B Schmidt; Blaz Rodic; Michael J Zvolensky Journal: Addict Behav Date: 2019-02-21 Impact factor: 3.913
Authors: Alessandro A Jammal; Nara G Ogata; Fábio B Daga; Ricardo Y Abe; Vital P Costa; Felipe A Medeiros Journal: Am J Ophthalmol Date: 2018-09-17 Impact factor: 5.258
Authors: Lorra Garey; Andrew H Rogers; Kara Manning; Tanya Smit; Jaye L Derrick; Andres G Viana; Norman B Schmidt; Michael J Zvolensky Journal: J Subst Abuse Treat Date: 2019-10-30
Authors: Paul T Harrell; Syeda Mahrukh Hussnain Naqvi; Andrew D Plunk; Ming Ji; Silvia S Martins Journal: Am J Drug Alcohol Abuse Date: 2016-09-26 Impact factor: 3.829
Authors: Katie Witkiewitz; Corey R Roos; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Megan Kirouac; Alyssa A Forcehimes; Adam D Wilson; Charles S Robinson; Elizabeth McCallion; J Scott Tonigan; Nick Heather Journal: J Stud Alcohol Drugs Date: 2017-01 Impact factor: 2.582
Authors: Nicole A Short; Brittany M Mathes; Brittany Gibby; Mary E Oglesby; Michael J Zvolensky; Norman B Schmidt Journal: Addict Res Theory Date: 2016-06-29